PMID- 18561508
OWN - NLM
STAT- MEDLINE
DCOM- 20080710
LR  - 20240322
IS  - 1176-6344 (Print)
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Linking)
VI  - 4
IP  - 2
DP  - 2008
TI  - Orlistat in the prevention of diabetes in the obese patient.
PG  - 325-36
AB  - There has been an increase in the concern about preventing type 2 diabetes 
      mellitus (T2DM), a disease with great and increasing prevalence. The prevalence 
      of obesity, physical inactivity, Western processed diet, important risk factors 
      for the development of T2DM, are also rising. Free fatty acids are increased in 
      obesity and reduce insulin clearance and increase hepatic glucose production. 
      Implementation of a healthy lifestyle has been show to slow the progression of 
      impaired glucose tolerance to T2DM. Orlistat is an inhibitor of lipase activity, 
      with proved efficacy in body weight reduction and long-term management of obesity 
      and more favorable effects on carbohydrate metabolism and it was prospectively 
      shown in XENDOS study that orlistat promoted long-term weight loss and prevented 
      T2DM onset in obese individuals with normal and impaired glucose tolerance at 
      baseline over four years. This benefit could be associated to the weight loss 
      itself, to the limited absorption of lipids and reduction of plasma free fatty 
      acids, to increased production of incretins or to modulation of secretion of 
      cytokines by adipocytes, all effects secondary to orlistat treatment. A proposed 
      strategy is to identify subjects at highest risk to receive a drug intervention, 
      using lifestyle interventions alone at the community level.
FAU - Mancini, Marcio C
AU  - Mancini MC
AD  - Obesity and Metabolic Syndrome Group, Endocrinology and Metabolism Department, 
      Faculty of Medicine, University of Sao Paulo, Sao Paulo, SP, Brazil. 
      mmancini@usp.br
FAU - Halpern, Alfredo
AU  - Halpern A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Lactones)
RN  - 95M8R751W8 (Orlistat)
SB  - IM
MH  - Anti-Obesity Agents/*therapeutic use
MH  - Diabetes Mellitus, Type 2/etiology/physiopathology/*prevention & control
MH  - Diet/adverse effects
MH  - Exercise
MH  - Humans
MH  - Lactones/*therapeutic use
MH  - Life Style
MH  - Obesity/complications/*drug therapy/physiopathology
MH  - Orlistat
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Weight Loss
PMC - PMC2496972
EDAT- 2008/06/20 09:00
MHDA- 2008/07/11 09:00
PMCR- 2008/08/01
CRDT- 2008/06/20 09:00
PHST- 2008/06/20 09:00 [pubmed]
PHST- 2008/07/11 09:00 [medline]
PHST- 2008/06/20 09:00 [entrez]
PHST- 2008/08/01 00:00 [pmc-release]
AID - 10.2147/vhrm.s6808 [doi]
PST - ppublish
SO  - Vasc Health Risk Manag. 2008;4(2):325-36. doi: 10.2147/vhrm.s6808.